Global Capsule Endoscopy Market Size, Trend & Opportunity Analysis Report, by Type (Small Bowel Capsule Endoscopy, Oesophageal Capsule Endoscopy), Application (OGIB, Crohn-s Disease), and Forecast, 2025-2035
Global Capsule Endoscopy Market Size, Opportunity Analysis and Forecast, 2025-2035
Market Definition and Introduction
The Global Capsule Endoscopy Market, valued at USD 443.8 million in 2024, is projected to surge to USD 1,034.78 million by 2035, advancing at a robust CAGR of 8.00% during the forecast period 2025-2035. A growing demand for non-invasive diagnostics has spurred a major paradigm shift toward gastrointestinal disorders. Capsule endoscopy secures a position as an alternative in greater measure to conventional endoscopic procedures that offer complete visualisation of the small bowel and oesophagus with little to no discomfort imparted to the patient. It has arisen in modern-day medical diagnostics as a mainstay because of its ability to assess obscure gastrointestinal bleeding (OGIB), Crohn's disease, and various other GI abnormalities.
The advent of this technology, with respect to AI for image analysis and longer battery life, is driving the expansion of the industry due to the twin motivations of enhancing diagnostic accuracy and patient compliance. Furthermore, the growing incidence of chronic GI diseases and the ageing population are factors driving capsule endoscopy adoption. Regulatory approvals of innovative capsule designs and the integration of wireless connectivity to allow real-time data transmission continue to fuel market penetration.
In developing economies, high procedure costs and limited reimbursement policies may restrict market growth. Nevertheless, minimally invasive diagnostics and the increased focus on early disease detection will offer long-term demand. Strategic partnerships between medical device manufacturers and healthcare practitioners will further spur innovative developments, ensuring the market remains agile and responsive to ever-shifting clinical needs.
Recent Developments in the Industry
- In January 2024, Medtronic debuted its PillCam SB 3 system which uses advanced adaptive frame rate technology for enhanced lesion detection. The latest introduction is expected to improve workload efficiency in diagnostics and increase pathology detection rates within the small bowel, further boosting the already-celebrated position Medtronic holds in the capsule endoscopy market.
- In June 2024, Olympus Corporation announced a partnership with various top hospitals to test the endoscopic capsule that uses AI and machine learning to detect anomalies in real time. The outcomes of the innovation are expected to reduce the time taken for diagnosis and enhance the accuracy of diagnoses, especially in patients with complicated conditions such as Crohn's disease and OGIB.
- in March 2024, The FDA gave clearance to the MiroCam- oesophageal capsule made by South Korea's IntroMedic Co., Ltd. It's intended for purposes connected with Barrett's oesophagus and the complications associated with GERD. The imaging provided by the device is ultra-high resolution, and the battery life was lengthened, setting new benchmarks in oesophageal diagnostics.
Market Dynamics
Rising Adoption of Minimally Invasive Diagnostics Enhances Market Penetration and Patient-Centric Care
The increasing global demand for minimally invasive diagnostic procedures is a key growth driver for the capsule endoscopy market. Unlike traditional endoscopy, capsule-based procedures provide painless visualisation of the gastrointestinal tract without anaesthesia, discomfort, or hospitalisation. This patient-friendly approach, combined with wireless connectivity and rapid image transmission, has accelerated uptake across hospitals and speciality gastroenterology clinics. Rising incidences of Crohn’s disease, colorectal cancer, and obscure gastrointestinal bleeding are further fueling demand. Additionally, favourable reimbursement frameworks in developed markets enhance accessibility, making capsule endoscopy an increasingly preferred solution for both patients and providers.
High Costs of Devices and Procedures Pose Challenges to Broader Market Accessibility
Despite strong adoption, the market faces barriers due to the high cost of capsule devices and diagnostic procedures. Advanced systems incorporating panoramic imaging, extended battery life, and AI-based lesion detection are priced significantly higher than conventional endoscopy methods. In regions with limited reimbursement, such as parts of Latin America, Asia-Pacific, and the Middle East, this premium pricing restricts patient adoption. Safety concerns related to capsule retention in patients with strictures or narrowed GI pathways further limit universal acceptance. These cost and safety challenges continue to create hurdles to widespread penetration, particularly in price-sensitive and emerging markets.
Integration of AI and Remote Monitoring Creates Emerging Growth Opportunities Globally
Artificial intelligence and telemedicine integration present significant growth avenues for capsule endoscopy. AI algorithms now assist clinicians by automating lesion, bleeding, and polyp detection, reducing interpretation errors and turnaround times. Remote monitoring solutions, such as Medtronic’s PillCam SB3 @HOME, allow patients to undergo procedures at home, enhancing convenience and accessibility, especially in underserved regions. This convergence of AI and remote diagnostics not only addresses the shortage of gastroenterologists but also enables broader patient outreach. As healthcare systems increasingly invest in digital health, these innovations are expected to expand adoption across developed and developing economies.
Technological Advancements and Next-Generation Devices Drive Market Expansion Across Specialities
Continuous technological innovation is reshaping capsule endoscopy beyond small bowel evaluation. Emerging devices feature magnetically controlled navigation, robotic-assisted guidance, and 360-degree imaging capabilities, enabling diagnostics for the oesophagus and colon. Improvements in frame rates, battery efficiency, and image resolution further strengthen diagnostic accuracy. Regulatory milestones, such as Medtronic’s PillCam Genius SB approval, underscore the industry’s innovation momentum. These advancements expand clinical applications, reduce dependency on traditional invasive methods, and solidify capsule endoscopy’s position as a frontline diagnostic modality across multiple gastrointestinal specialties.
Global Disparities in Awareness, Training, and Reimbursement Remain Key Challenges
Unequal adoption across regions remains a challenge, with disparities in physician training, infrastructure, and reimbursement policies. In many developing economies, capsule endoscopy remains underutilised due to a lack of awareness, inadequate training, and high device costs. Fragmented reimbursement frameworks in Asia-Pacific and Latin America further constrain uptake. Structured training programs, such as those introduced by United European Gastroenterology(UEG), are critical to ensuring consistent diagnostic reliability. Bridging these gaps through education, public-private partnerships, and regulatory alignment will be essential to unlocking the full growth potential of the capsule endoscopy market.
Attractive Opportunities in the Market
- AI Integration - Machine learning algorithms enhancing diagnostic accuracy and workflow efficiency
- Expanded Indications - Growing use of capsule endoscopy in colorectal and oesophageal cancer screening
- Telemedicine Synergy - Remote monitoring capabilities aligning with telehealth trends
- Portable Readers - Compact, wireless readers facilitating point-of-care diagnostics
- Biodegradable Capsules - Eco-friendly solutions reducing environmental impact
- Emerging Economies - Untapped potential in Asia-Pacific and Latin American markets
- Reimbursement Expansion - Advocacy for broader insurance coverage to boost adoption
- Collaborative R&D - Partnerships between medtech firms and research institutions
- Patient-Centric Designs - Enhanced comfort and swallowability, improving compliance
- Regulatory Approvals - Faster clearances for next-gen devices, accelerating market entry
Report Segmentation
By Type: Small Bowel Capsule Endoscopy, Oesophageal Capsule Endoscopy
By Application: OGIB, Crohn-s Disease
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
Key Market Players: Medtronic plc, Olympus Corporation, IntroMedic Co., Ltd., Chongqing Jinshan Science & Technology Group Co., Ltd., Check-Cap Ltd., RF System lab, CapsoVision Inc., Fujifilm Holdings Corporation, AnX Robotica, Given Imaging (a Medtronic company)
Report Aspects
Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2025-2035
Report Pages: 293
Dominating Segments
Small Bowel Capsule Endoscopy Dominates Global Market with Strong Adoption inGastrointestinal Disorder Diagnostics.
In 2024, small bowel capsule endoscopy emerged as the largest type segment, accounting for 54.6% of global revenues. Its dominance stems from unmatched efficacy in diagnosing obscure gastrointestinal bleeding (OGIB), Crohn’s disease, celiac disease, and small bowel tumours. Traditional endoscopy methods face limitations in accessing the small intestine, whereas capsule devices offer complete visualisation with superior patient comfort. The adoption of advanced devices such as Medtronic’s PillCam Genius SB, featuring AI-driven lesion detection and longer battery life, has further reinforced the technology’s clinical relevance. Favourable reimbursement structures in North America and Europe, coupled with the growing global prevalence of gastrointestinal disorders, continue to underpin its leadership. Hospitals and diagnostic centres increasingly prefer this modality, highlighting its role as the gold standard in small bowel imaging.
Colon Capsule Endoscopy Registers Fastest Growth Driven by Rising Colorectal Cancer Screening Programs Worldwide.
Colon capsule endoscopy is projected to grow at the fastest CAGR during the forecast period, supported by the rising global prevalence of colorectal cancer. Developed markets, including the U.S., Germany, and Japan, are expanding national screening programs, driving adoption of minimally invasive alternatives. Colon capsule technology eliminates the need for sedation, invasive procedures, and hospitalization, offering a more patient-friendly diagnostic pathway. Recent advancements, such as panoramic imaging and AI-assisted automated polyp detection, are enhancing diagnostic reliability and clinician confidence. Preventive healthcare initiatives across North America and Europe further accelerate uptake. As healthcare systems aim to expand early detection coverage and reduce cancer-related mortality, colon capsule endoscopy is expected to emerge as the most lucrative growth driver in this market.
Obscure Gastrointestinal Bleeding (OGIB) Application Leads Market with Highest Adoption Across Diagnostic and Specialty Centers.
Obscure gastrointestinal bleeding (OGIB) dominated the market by application in 2024, capturing a 45.4% revenue share. Capsule endoscopy is now the global standard of care for identifying bleeding sources within the small intestine, surpassing the limitations of conventional diagnostic approaches. The integration of AI-powered platforms has significantly improved detection accuracy, helping clinicians localize bleeding more efficiently while reducing diagnostic time. With OGIB contributing to a substantial proportion of GI-related hospitalizations worldwide, demand for capsule endoscopy remains consistently high. The prevalence of conditions such as Crohn’s disease, ulcers, and vascular malformations further fuels demand for reliable bleeding detection. Diagnostic centres and hospitals are prioritising capsule-based evaluations, ensuring OGIB remains the cornerstone of market adoption.
Small Intestine Tumour Application Poised for Fastest Growth with Rising Early Cancer Detection Requirements.
The small intestine tumor application segment is forecasted to witness the fastest growth during the next decade, driven by the need for early cancer detection. Capsule endoscopy offers high-resolution imaging that enables reliable diagnosis of rare but clinically significant small bowel tumours, often missed by traditional imaging techniques. Growing global cancer incidence, particularly in Asia-Pacific and Europe, is amplifying demand for precise and less invasive diagnostic tools. Increasing inclusion of capsule endoscopy in clinical guidelines for suspected small bowel tumours strengthens its market positioning. Furthermore, technological innovationssuch as AI-assisted lesion detection, improved battery longevity, and enhanced image captureare expanding adoption in oncology diagnostics. As healthcare systems emphasize early diagnosis to reduce treatment costs and mortality, this segment is set to gain strong momentum.
Key Takeaways
- Small Bowel Dominance - Preferred for comprehensive GI tract visualisation
- OGIB Growth - Rising adoption due to non-invasive diagnostic advantages
- AI Revolution - Machine learning transforming image analysis and reporting
- Cost Barriers - High procedural expenses limit emerging market penetration
- Regulatory Momentum - Faster approvals for innovative capsule designs
- Asia-Pacific Boom - Expanding healthcare access drives regional demand
- Eco-Friendly Trends - Biodegradable capsules gaining traction
- Strategic Alliances - Collaborations accelerating R&D and market reach
Regional Insights
North America Leads Capsule Endoscopy Market with High Disease Prevalence and Strong Technological Adoption Rates
In 2024, North America dominated the capsule endoscopy market with a 43.6% revenue share, supported by the high prevalence of gastrointestinal (GI) disorders, Crohn’s disease, obscure GI bleeding, celiac disease, and colorectal cancer. The U.S. drives most of the region’s demand, with increasing patient preference for minimally invasive procedures and supportive reimbursement frameworks encouraging adoption. Regulatory approvals from the FDA for advanced capsule technologies, such as AI-enabled platforms and magnetically controlled capsules, have further boosted growth. The expansion of home-based diagnostic solutions, such as Medtronic’s PillCam SB3 @HOME program, highlights the region’s push toward patient-centric care. Strong healthcare infrastructure, advanced gastroenterology practices, and rising awareness of preventive screenings solidify North America’s leadership in the global market.
Europe Witnesses Strong Growth from Favourable Screening Programs and Expanding Gastrointestinal Cancer Diagnosis Needs
The European capsule endoscopy market is projected to experience significant growth, driven by favourable colorectal cancer screening initiatives and high adoption in countries like Germany, the UK, and France. Less stringent regulatory processes for medical devices compared to North America have accelerated the launch of innovative products, supporting wider availability across hospitals and diagnostic centres. Germany, with its rising cancer incidence, remains a key growth driver, where capsule endoscopy is increasingly integrated into standard diagnostic protocols. Rising disposable incomes, well-established healthcare systems, and an expanding pool of skilled gastroenterologists further boost adoption. Additionally, training programs such as those led by the United European Gastroenterology (UEG) are strengthening professional expertise, ensuring capsule endoscopy becomes an integral part of routine clinical practice in Europe over the forecast period.
Asia-Pacific Registers Fastest Growth with Expanding Patient Base, Rising Investments, and Advanced Healthcare Infrastructure.
The Asia-Pacific capsule endoscopy market is anticipated to grow at the fastest CAGR through 2035, driven by the region’s large patient pool, increasing incidence of GI cancers, and growing demand for advanced diagnostic technologies. Countries like China, Japan, India, and South Korea are investing heavily in healthcare infrastructure, digital health innovations, and physician training programs. China, in particular, is witnessing rapid adoption due to rising healthcare expenditures and initiatives such as Olympus China’s medical training centres. India is expected to register the highest CAGR between 2025 and 2035, fueled by increasing awareness of early cancer detection and growing access to advanced medical devices. With regional governments promoting preventive care and private players expanding distribution networks, the Asia-Pacific is poised to be the most dynamic growth hub for capsule endoscopy.
Rest of the World Gains Momentum with Rising Awareness and Expanding Access to Diagnostic Procedures.
The Rest of the World (RoW) capsule endoscopy market, covering Latin America, the Middle East, and Africa, is projected to expand steadily during the forecast period. Brazil and Mexico are emerging as key growth drivers in Latin America, supported by rising healthcare demand, favorable government initiatives, and increased investments from global medical device companies. In the Middle East and Africa, countries such as Saudi Arabia, South Africa, and the UAE are witnessing growth from expanding hospital infrastructure and a rising preference for minimally invasive diagnostics. Training initiatives by organizations like the World Gastroenterology Organisation (WGO) in African countries are also fostering awareness and accessibility. With an increasing burden of gastrointestinal diseases and gradual improvements in healthcare systems, RoW is expected to unlock significant untapped opportunities for capsule endoscopy.
Key Benefits for Stakeholders
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Frequently Asked Question(FAQ) :
Small bowel capsule endoscopy is the dominating segment, accounting for 54.6% of global revenues in 2024. Its leadership is attributed to its unmatched efficacy in diagnosing conditions like Crohn’s disease and obscure gastrointestinal bleeding (OGIB), which are often difficult to reach via traditional endoscopy.
Obscure Gastrointestinal Bleeding (OGIB) is the leading application, capturing a 45.4% revenue share in 2024. Capsule endoscopy has become the global gold standard for identifying bleeding sources within the small intestine that conventional diagnostic tools cannot easily access.
The Asia-Pacific region is anticipated to register the fastest CAGR. This growth is driven by a large patient pool, increasing incidences of gastrointestinal cancers, rising healthcare expenditures, and significant infrastructure investments in countries like China, India, and South Korea.
AI is a major growth driver used to automate the detection of lesions, polyps, and bleeding. Recent developments, such as Olympus Corporation’s AI-integrated capsules, aim to reduce diagnostic time and interpretation errors while enhancing accuracy for complex conditions like Crohn’s disease.
The market faces challenges in developing regions due to the high cost of advanced capsule devices and procedures. Additionally, limited reimbursement policies and a lack of specialized physician training in parts of Latin America, Asia-Pacific, and Africa restrict broader patient adoption.
The small intestine tumor application is poised for the fastest growth. This is driven by an increasing global emphasis on early cancer detection and the development of high-resolution imaging and AI-assisted tools that can identify rare but clinically significant tumors.
In 2024, Medtronic debuted the PillCam SB 3 with adaptive frame rate technology, and IntroMedic Co., Ltd. received FDA clearance for the MiroCam-oesophageal capsule. These innovations focus on improving lesion detection, battery life, and diagnostic efficiency.
Telemedicine is creating new growth avenues through remote monitoring solutions, such as Medtronic’s PillCam SB3 @HOME. These programs allow patients to undergo diagnostic procedures in their own homes, addressing the shortage of gastroenterologists and increasing accessibility in underserved regions.
The market is led by prominent medical technology companies, including Medtronic plc, Olympus Corporation, IntroMedic Co., Ltd., Chongqing Jinshan Science & Technology Group Co., Ltd., and Fujifilm Holdings Corporation.
